title: [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer].
abstract: A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer.
  
  
  METHODS
  Numerous studies have proved the efficacy of tamoxifen treatment in women with receptor-positive breast cancer. Preclinical and phase I/II-studies showed that tumor control can be improved if Octreotid is added. In this randomized controlled double blind phase III study women received 20 mg tamoxifen daily and either 160 mg Octreoid-Depot i. m. injection once a month or a placebo injection. Until 1998 a total of 263 women were randomized.
  
  
  RESULTS
  The study medication was tolerated well by all patients in the treatment group (n = 133). The most frequent moderate side effects were diarrhea (n = 73), nausea (n = 26), abdominal pain (n = 19), bone pain (n = 24) and fatigue (n = 20). No patient dropped out because of these side effects. Surprisingly, several complete remissions occured. Neither the total survival nor the progression free survival was significantly different between groups. Therefore the study was stopped before the originally planned number of patients (n = 416) had been enrolled.
  
  
  CONCLUSIONS
  Octreotid plus tamoxifen does not improve tumor control. It is necessary to define subgroups that might benefit from Octreotid.
authors.affiliation: Universitäts-Frauenklinik Klinikum Innenstadt der LMU München, Germany. Harald.Sommer@fk-i.med.uni-muenchen.de
authors.forename: H
authors.initials: H
authors.lastname: Sommer
authors.forename: B
authors.initials: B
authors.lastname: Pröhl-Steimer
authors.forename: E
authors.initials: E
authors.lastname: Bajetta
authors.forename: U
authors.initials: U
authors.lastname: Haus
authors.forename: W
authors.initials: W
authors.lastname: Janni
authors.forename: A
authors.initials: A
authors.lastname: Kay
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000401:mortality; D015282:Octreotide / Q000008:administration & dosage* / Q000009:adverse effects; D010166:Palliative Care; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D013629:Tamoxifen; D015282:Octreotide